Pharmafile Logo
Pharmafocus logo
Advanced Search

intercept

Showing 3 posts of 3 posts found.

NICE approves first biliary cholangitis drug in 20 years

March 2, 2017
Sales and Marketing Intercept Pharmaceuticals, intercept, liver disease, ocaliva, primary biliary cholangitis

Intercept Pharmaceuticals has announced that Ocaliva (obeticholic acid) has been approved by the National Institute for Health and Care Excellence …

News
ema_building_face_web

EMA grants conditional approval for biliary cholangitis treatment

October 17, 2016
Sales and Marketing EMA, intercept, ocaliva, primary biliary cholangitis

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has voiced its approval of Intercept’s Ocaliva …

News
clinical_trial_3

Intercept’s Ocaliva meets primary endpoint in Phase III trial for rare liver disease

August 18, 2016
Medical Communications, Research and Development intercept, ocaliva

Intercept Pharmaceuticals have announced the publication of Phase III results published in the New England Journal of Medicine, where Ocaliva …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024